Table 2. Suggestions regarding target population and eligibility.

Age: 12-17 years old (once safety/efficacy is established in this age-group, trials of younger children can be initiated) BMI ≥95th percentile (depending upon the risk/benefit of the agent(s) under investigation, requirement of ≥1 co-morbid condition may be appropriate) Tanner stage: no lower limit unless evidence suggests developmental risk of specific agent No upper BMI threshold (can consider sub-analyses by BMI categories) Include participants taking potentially weight altering medication(s) with stable dose for ≥6 months Observed or documented history of failed weight loss attempts unnecessary